This site uses cookies to bring you the best experience. Find out more
Skip to main content

News

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn  

Media enquiries: comms@oxfordsp.com 


Scancell’s Modi-1 Moditope® vaccine achieves early clinical validation in head and neck cancer.

Modi-1 successfully achieved Simon stage 1 suggesting the combination of Modi-1 and checkpoint blockade is beneficial in HPV negative head and neck squamous cell carcinoma (SCCHN) This result supports the continuation of the study in this indication Moditope® patent granted by U.S. Patent and Trademark Office (USPTO) Scancell, a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, has achieved significant... Read more